Contrast-Enhanced Mammography for Breast Cancer
(CEM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines a new method for screening breast cancer in women with dense breast tissue and a personal history of breast cancer. It employs Contrast-Enhanced Mammography (CEM), which combines a regular mammogram with a special dye to detect tumors that traditional methods might miss. The trial aims to determine if CEM outperforms ultrasound and MRI by evaluating its cancer detection rate and patient satisfaction. Women with dense breasts and a clean mammogram, who are awaiting further screening, may be suitable candidates for this trial. As an unphased trial, it offers a unique opportunity to contribute to innovative screening methods that could enhance early detection for many women.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that Contrast-Enhanced Mammography is safe for breast cancer screening?
Research shows that Contrast-Enhanced Mammography (CEM) is generally safe and well-tolerated. CEM uses a special dye to enhance tumor visibility during breast cancer screening. Studies have found that CEM is highly effective at detecting cancer, with accuracy rates between 89% and 97.7%, and it correctly identifies non-cancerous cases 50% to 89% of the time. This makes CEM particularly effective for women with dense breast tissue.
While studies primarily focus on CEM's cancer detection capabilities, they report very few side effects, suggesting CEM is safe for most people. The use of contrast dyes is common in medical imaging, and serious side effects are rare. However, mild reactions like warmth or a metallic taste can occur. Those concerned about dye allergies should consult a doctor before joining a trial.12345Why are researchers excited about this trial?
Contrast-Enhanced Mammography (CEM) is unique because it combines standard mammography with an iodinated contrast medium to enhance the visualization of breast lesions. This is particularly beneficial for women with dense breast tissue, where traditional mammograms might miss some cancers. Researchers are excited about CEM because it has the potential to improve cancer detection rates and reduce false positives, leading to more accurate diagnosis and fewer unnecessary biopsies.
What evidence suggests that Contrast-Enhanced Mammography is effective for breast cancer screening?
Research has shown that Contrast-Enhanced Mammography (CEM), which participants in this trial will undergo, effectively detects breast cancer, particularly in women with dense breast tissue. Studies have found that CEM correctly identifies all cancer cases in dense breasts. Compared to traditional ultrasound, CEM and a shorter version of breast MRI detect three times more invasive cancers. Adding CEM to regular screenings significantly enhances early cancer detection. This evidence suggests that CEM is a powerful tool for early breast cancer screening, offering better visibility of tumors and reducing missed cases.23678
Who Is on the Research Team?
Dr. Jean Seely Principal Investigator,, MD FRCPC
Principal Investigator
Ottawa Hospital Research Institute
Are You a Good Fit for This Trial?
This trial is for women with dense breast tissue who have had breast cancer before. It's testing if a special mammogram using contrast dye can find tumors better than usual methods. Women must be past their initial treatments and screenings to join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Contrast-Enhanced Mammography
Participants undergo Contrast-Enhanced Mammography (CEM) as a supplemental screening method for breast cancer
Follow-up
Participants are monitored for cancer detection rates, biopsy results, and patient satisfaction over two years
Procedure Safety Monitoring
Monitor and report any adverse events, including allergic reactions to the contrast medium and other side effects
What Are the Treatments Tested in This Trial?
Interventions
- Contrast-Enhanced Mammography
Trial Overview
The study tests Contrast-Enhanced Mammography (CEM) against traditional ultrasound and MRI in detecting breast cancer. Participants will undergo CEM to see if it's more accurate, faster, and cost-effective for those with dense breasts.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
This arm involves participants undergoing Contrast-Enhanced Mammography (CEM) as a supplemental screening method for breast cancer. CEM combines standard mammography with iodinated contrast medium to improve lesion visualization and tumor detection, particularly in women with dense breast tissue. Participants will receive CEM during a single visit at the Rose Ages Breast Health Centre, and their results will be evaluated for cancer detection, abnormal interpretation rates, and biopsy outcomes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jean Seely
Lead Sponsor
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Industry Sponsor
Citations
The effectiveness of contrast-enhanced spectral ...
Material analysis demonstrated both CESM and MRI sensitivity in dense breasts to be 100%. Until now, only the general sensitivity and specificity of both ...
Contrast-enhanced Mammography in Women With a ...
The primary outcome measure is the detection rate of breast cancer in women with dense breast tissue using contrast-enhanced mammography (CEM). The sensitivity ...
Screening for Breast Cancer with Contrast-enhanced ...
Adding contrast-enhanced mammography to digital breast tomosynthesis significantly increased early breast cancer detection alongside a 13% increase in the ...
Comparison of supplemental breast cancer imaging ...
Abbreviated breast MRI and contrast-enhanced mammography detected three times as many invasive cancers than whole breast ultrasound. The ...
Contrast-Enhanced Mammography: Bridging the research ...
Interim results have demonstrated that supplemental contrast imaging facilitate earlier cancer detection in women with dense breasts, without significant ...
Contrast-Enhanced Mammography in Breast Cancer Screening
The overall cancer detection rate was 15.5 per 1000 women, which is similar to MRI. Follow-up data for these patients are currently pending. Among a small ...
Evaluating ten years of breast cancer screening with ...
The cancer detection rate for CEM was 13.1 per 1,000 cases, and the AUC was 0.923. Conclusions. CEM is a viable breast cancer screening method for women with ...
Contrast-enhanced mammography in high-dense breasts
CEM demonstrates high sensitivity (89–97.7%) and specificity (50–89%) in detecting malignancies within dense breasts, offering comparable diagnostic accuracy ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.